PLoS ONE (Jan 2023)

Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis.

  • Yu Xiong,
  • Xiumei Guo,
  • Xinyue Huang,
  • Xiaodong Kang,
  • Jianfeng Zhou,
  • Chunhui Chen,
  • Zhigang Pan,
  • Linxing Wang,
  • Roland Goldbrunner,
  • Lampis Stavrinou,
  • Pantelis Stavrinou,
  • Shu Lin,
  • Yuping Chen,
  • Weipeng Hu,
  • Feng Zheng

DOI
https://doi.org/10.1371/journal.pone.0282726
Journal volume & issue
Vol. 18, no. 3
p. e0282726

Abstract

Read online

BackgroundAlthough some studies have shown that tranexamic acid is beneficial to patients with intracranial haemorrhage, the efficacy and safety of tranexamic acid for intracranial haemorrhage remain controversial.MethodThe PubMed, EMBASE, and Cochrane Library databases were systematically searched. The review followed PRISMA guidelines. Data were analyzed using the random-effects model.ResultsTwenty-five randomized controlled trials were included. Tranexamic acid significantly inhibited hematoma growth in intracranial hemorrhage (ICH) and traumatic brain injury (TBI) patients. (ICH: mean difference -1.76, 95%CI -2.78 to -0.79, I2 = 0%, P ConclusionTranexamic acid can significantly reduce the risk of intracranial haemorrhage growth in patients with ICH and TBI. Tranexamic acid can reduce the incidence of complications (hydrocephalus, rebleeding) in patients with SAH, which can indirectly improve the quality of life of patients with intracranial haemorrhage.